keyword
MENU ▼
Read by QxMD icon Read
search

Brintellix

keyword
https://www.readbyqxmd.com/read/27807822/vortioxetine-a-review-in-cognitive-dysfunction-in-depression
#1
James E Frampton
Vortioxetine (Brintellix(®); Trintellix(®)), a generally efficacious and well tolerated antidepressant agent, is approved in the EU and USA for the treatment of major depressive disorder (MDD) in adults. The drug has a distinctive pharmacological profile (combining inhibition of the serotonin transporter with modulation of multiple serotonin receptors) and has been shown to enhance cognitive performance in various animal models and clinical trials. Across three large, placebo-controlled studies in adults with recurrent MDD, short-term treatment with vortioxetine almost always resulted in statistically significant and clinically meaningful improvements in performance on two objective measures (the Digit Symbol Substitution Test and Rey Auditory Verbal Learning Test) that together cover a broad range of cognitive domains, including executive function, attention, processing speed, learning and memory...
November 2016: Drugs
https://www.readbyqxmd.com/read/27781949/current-and-future-perspectives-on-the-major-depressive-disorder-focus-on-the-new-multimodal-antidepressant-vortioxetine
#2
Laura Orsolini, Carmine Tomasetti, Alessandro Valchera, Felice Iasevoli, Elisabetta Filomena Buonaguro, Michele Fornaro, Annastasia L C Fiengo, Giovanni Martinotti, Federica Vellante, Ilaria Matarazzo, Roberta Vecchiotti, Giampaolo Perna, Marco Di Nicola, Alessandro Carano, Andrea de Bartolomeis, Massimo Di Giannantonio, Domenico De Berardis
BACKGROUND: Vortioxetine (VRX) is a multimodal antidepressant that acts as serotonin (5¬HT) transporter inhibitor as well as 5¬HT3A and 5¬HT7 receptors antagonist, 5¬HT1A and 5¬HT1B receptors partial agonist. It was recently approved in the US and the EU for the treatment of adult patients with Major Depressive Disorder (MDD). OBJECTIVE: The present article aims at systematically reviewing findings of the published and unpublished research on the pharmacological properties, efficacy, safety and tolerability of oral VRX in the treatment of major depressive disorder (MDD)...
October 25, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27387386/clinical-psychopharmacology-update-what-s-in-a-name-confusion-prompts-change-for-vortioxetine-s-brand-name
#3
Thomas J Tobin, Mary L Tobin
Similar names between two unrelated drugs have led the FDA to issue warnings about and now approve a name change for vortioxetine, which was branded as Brintellix® until recently. While the trade name had been screened prior to the product's launch, the FDA received numerous reports of prescribing and dispensing errors, specifically with regard to the anti-coagulant drug Brilinta® (ticagrelor). Starting 1 June 2016, vortioxetine will be marketed under the name Trintellix™ in an effort to reduce confusion...
July 7, 2016: Issues in Mental Health Nursing
https://www.readbyqxmd.com/read/26966120/what-role-for-%C3%A2-vortioxetine
#4
(no author information available yet)
▼Vortioxetine (Brintellix-Lundbeck) is licensed for treating adults with major depressive episodes.(1) It acts on the serotonin system and is described as having a 'novel multimodal mechanism of action'.(2) The company claims that it is the first antidepressant in the EU to include an effect on certain aspects of cognitive function in patients with depression in its Summary of Product Characteristics.(3) The National Institute for Health and Care Excellence has recommended it as an option for patients whose current episode has responded inadequately to two antidepressants...
March 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/26879252/-pharmacological-properties-of-vortioxetine-and-its-pre-clinical-consequences
#5
D J David, L Tritschler, J-P Guilloux, A M Gardier, C Sanchez, R Gaillard
Selective Serotonin Reuptake Inhibitors (SSRIs) are extensively used for the treatment of major depressive disorder (MDD). SSRIs are defined as indirect receptor agonists since the activation of postsynaptic receptors is a consequence of an increase in extracellular concentrations of serotonin (5-HT) mediated by the blockade of serotonin transporter. The activation of some serotoninergic receptors (5-HT1A, post-synaptic, 5-HT1B post-synaptic, 5-HT2B, and 5-HT4), but not all (5-HT1A, pre-synaptic, 5-HT1B pre-synaptic, 5-HT2A, 5-HT2C, 5-HT3, and probably 5-HT6), induces anxiolytic/antidepressive - like effects...
February 2016: L'Encéphale
https://www.readbyqxmd.com/read/25822390/vortioxetine-brintellix-for-the-treatment-of-depression
#6
Megan K Magovern, Katharine C DeGeorge
No abstract text is available yet for this article.
March 1, 2015: American Family Physician
https://www.readbyqxmd.com/read/25628505/vortioxetine-brintellix-a-new-serotonergic-antidepressant
#7
Andrew D'Agostino, Clayton D English, Jose A Rey
Vortioxetine (Brintellix): a new serotonergic antidepressant.
January 2015: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25426751/vortioxetine-brintellix%C3%A2-and-levomilnacipran-fetzima%C3%A2-the-two-newest-additions-to-the-antidepressant-formulary
#8
Marian W Roman, Shannon M Wilkinson
In the final months of 2013, the US Food and Drug Administration approved two new antidepressant formulations. This column presents a review of the pertinent literature on both: vortioxetine (Brintellix(®)) and levomilnacipran (Fetzima(®)).
December 2014: Issues in Mental Health Nursing
https://www.readbyqxmd.com/read/25418918/the-efficacy-of-vortioxetine-for-the-treatment-of-major-depressive-disorder
#9
REVIEW
Ashish Dhir, Jayrajsinh Sarvaiya
Vortioxetine (Lu AA21004; Brintellix(®)) has received approval from various international regulatory agencies for the treatment of major depression. The drug molecule has a multimodal mechanism of action that projects it as a unique molecule for the treatment of major depression. These mechanisms include property to inhibit serotonin reuptake via inhibiting serotonin transporters and acting on multiple serotonin receptor subtypes. Vortioxetine is an agonist of 5-HT1A, a partial agonist of 5-HT1B and an antagonist of 5-HT1D, 5-HT3 and 5-HT7 serotoninergic receptors...
December 2014: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/25166025/vortioxetine-for-the-treatment-of-major-depressive-disorder
#10
REVIEW
Laurent Tritschler, Daniela Felice, Romain Colle, Jean-Philippe Guilloux, Emmanuelle Corruble, Alain Michel Gardier, Denis Joseph David
Vortioxetine (Brintellix(®), 1-[2-(2,4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT3, 5-HT7 receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine administration induces antidepressant- and anxiolytic-like effects, and can enhance cognitive performance in rodents. Several clinical trials have reported the efficiency and a satisfactory tolerability of vortioxetine treatment in depressed patients. Remarkably, vortioxetine has a specific positive impact on cognitive symptoms in depressed patients...
November 2014: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/25145538/vortioxetine-a-review-of-its-use-in-major-depressive-disorder
#11
REVIEW
Karly P Garnock-Jones
Vortioxetine (Brintellix(®)) is a serotonin (5-HT) transporter inhibitor that also acts on several 5-HT receptors, such as the 5-HT3 and 5-HT1A receptors. It is approved in the US and the EU for the treatment of adult patients with major depressive disorder (MDD); this article reviews the pharmacological properties of oral vortioxetine and its clinical efficacy and tolerability in these patients. Vortioxetine is generally efficacious in patients with MDD in acute treatment trials (including elderly patients), in a relapse-prevention trial, and in open-label extension trials...
September 2014: CNS Drugs
https://www.readbyqxmd.com/read/24676550/vortioxetine-for-the-treatment-of-depression
#12
REVIEW
Erica F Pearce, Julie A Murphy
OBJECTIVE: To evaluate the clinical literature and potential clinical role of vortioxetine (Brintellix) for the treatment of major depressive disorder (MDD). DATA SOURCES: A MEDLINE search (1966-February 2014) was conducted using the search terms vortioxetine, Lu AA21004, and depression. Bibliographies of all articles retrieved were also reviewed. All references included were published between 1999 and 2014. STUDY SELECTION/DATA EXTRACTION: All studies that included humans and were published in English, with data describing vortioxetine for the treatment of MDD, were reviewed...
June 2014: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/24391391/pharmaceutical-approval-update
#13
Marvin M Goldenberg
Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma.
November 2013: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/24276501/vortioxetine-brintellix-for-depression
#14
(no author information available yet)
No abstract text is available yet for this article.
November 25, 2013: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"